Literature DB >> 35090157

Disengagement From HIV Care and Failure of Second-Line Therapy in Nigeria: A Retrospective Cohort Study, 2005-2017.

Kate El Bouzidi1,2, Fati Murtala-Ibrahim3, Vivian Kwaghe4, Rawlings P Datir5, Obinna Ogbanufe6, Trevor A Crowell7,8, Man Charurat9, Patrick Dakum3, Ravindra K Gupta5,10, Nicaise Ndembi3,9,11, Caroline A Sabin2.   

Abstract

BACKGROUND: Understanding the correlates of disengagement from HIV care and treatment failure during second-line antiretroviral therapy (ART) could inform interventions to improve clinical outcomes among people living with HIV (PLHIV).
METHODS: We conducted a retrospective cohort study of PLHIV aged >15 years who started second-line ART at a tertiary center in Nigeria between 2005 and 2017. Participants were considered to have disengaged from care if they had not returned within a year after each clinic visit. Cox proportional hazard models were used to investigate factors associated with: (1) viral failure (HIV-1 RNA >1000 copies/mL), (2) immunologic failure (CD4 count decrease or <100 cells/mm3), and (3) severe weight loss (>10% of bodyweight), after >6 months of second-line ART.
RESULTS: Among 1031 participants, 33% (341) disengaged from care during a median follow-up of 6.9 years (interquartile range 3.7-8.5). Of these, 26% (89/341) subsequently reentered care. Disengagement was associated with male gender, age <30 years, lower education level, and low CD4 count at second-line ART initiation. Among participants with endpoint assessments available, 20% (112/565) experienced viral failure, 32% (257/809) experienced immunologic failure, and 23% (190/831) experienced weight loss. A lower risk of viral failure was associated with professional occupations compared with elementary: adjusted hazard ratio 0.17 (95% confidence interval 0.04 to 0.70).
CONCLUSION: Adverse outcomes were common during second-line ART. However, reengagement is possible and resources should be allocated to focus on retaining PLHIV in care and providing services to trace and reengage those who have disengaged from care.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35090157      PMCID: PMC8986580          DOI: 10.1097/QAI.0000000000002918

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.771


  34 in total

Review 1.  Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection.

Authors:  Jamie D Croxtall; Caroline M Perry
Journal:  Drugs       Date:  2010-10-01       Impact factor: 9.546

2.  Correlates of Patient Retention in HIV Care and Treatment Programs in Nigeria.

Authors:  Chinenye Ugoji; Nwanneka Okere; Patrick Dakum; Rukeme Ake-Uzoigwe; Donald Igboelina; Nicaise Ndembi; Ernest Ekong; Manhattan Charurat; William A Blattner
Journal:  Curr HIV Res       Date:  2015       Impact factor: 1.581

3.  Body mass index at time of HIV diagnosis: a strong and independent predictor of survival.

Authors:  Marianne A B van der Sande; Maarten F Schim van der Loeff; Akum A Aveika; Saihou Sabally; Toyin Togun; Ramu Sarge-Njie; Abraham S Alabi; Assan Jaye; Tumani Corrah; Hilton C Whittle
Journal:  J Acquir Immune Defic Syndr       Date:  2004-10-01       Impact factor: 3.731

4.  Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program.

Authors:  Hermann Bussmann; C William Wester; Ndwapi Ndwapi; Nicolas Grundmann; Tendani Gaolathe; John Puvimanasinghe; Ava Avalos; Madisa Mine; Khumo Seipone; Max Essex; Victor Degruttola; Richard G Marlink
Journal:  AIDS       Date:  2008-11-12       Impact factor: 4.177

5.  Predictors of mortality among HIV infected patients taking antiretroviral treatment in Ethiopia: a retrospective cohort study.

Authors:  Sibhatu Biadgilign; Ayalu A Reda; Tesfaye Digaffe
Journal:  AIDS Res Ther       Date:  2012-05-18       Impact factor: 2.250

6.  Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.

Authors:  Dami Collier; Collins Iwuji; Anne Derache; Tulio de Oliveira; Nonhlanhla Okesola; Alexandra Calmy; Francois Dabis; Deenan Pillay; Ravindra K Gupta
Journal:  Clin Infect Dis       Date:  2017-04-15       Impact factor: 9.079

7.  High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment.

Authors:  Kate El Bouzidi; Steven A Kemp; Rawlings P Datir; Fati Murtala-Ibrahim; Ahmad Aliyu; Vivian Kwaghe; Dan Frampton; Sunando Roy; Judith Breuer; Caroline A Sabin; Obinna Ogbanufe; Man E Charurat; David Bonsall; Tanya Golubchik; Christophe Fraser; Patrick Dakum; Nicaise Ndembi; Ravindra K Gupta
Journal:  J Antimicrob Chemother       Date:  2020-06-01       Impact factor: 5.790

8.  Predictors of All-Cause Mortality Among People With Human Immunodeficiency Virus (HIV) in a Prospective Cohort Study in East Africa and Nigeria.

Authors:  Hannah Kibuuka; Ezra Musingye; Betty Mwesigwa; Michael Semwogerere; Michael Iroezindu; Emmanuel Bahemana; Jonah Maswai; John Owuoth; Allahna Esber; Nicole Dear; Trevor A Crowell; Christina S Polyak; Julie A Ake
Journal:  Clin Infect Dis       Date:  2022-09-10       Impact factor: 20.999

Review 9.  Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review.

Authors:  Sydney Rosen; Matthew P Fox; Christopher J Gill
Journal:  PLoS Med       Date:  2007-10-16       Impact factor: 11.069

10.  Predictors of first-line antiretroviral therapy failure among adults and adolescents living with HIV/AIDS in a large prevention and treatment program in Nigeria.

Authors:  Nicaise Ndembi; Fati Murtala-Ibrahim; Monday Tola; Jibreel Jumare; Ahmad Aliyu; Peter Alabi; Charles Mensah; Alash'le Abimiku; Miguel E Quiñones-Mateu; Trevor A Crowell; Soo-Yon Rhee; Robert W Shafer; Ravindra Gupta; William Blattner; Manhattan E Charurat; Patrick Dakum
Journal:  AIDS Res Ther       Date:  2020-11-03       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.